726192-01-4

Basic information

• Product Name: (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol
• Synonyms: (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol
• CAS NO: 726192-01-4
• Molecular Weight: 200.258
• Mol File: 726192-01-4.mol

Chemical Properties

• CAS DataBase Reference: (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol(726192-01-4)
• EPA Substance Registry System: (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol(726192-01-4)

Safety Data

• Hazardous Substances Data: 726192-01-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol is used as a building block for the synthesis of various drugs, particularly those with anti-inflammatory and analgesic properties. Its unique structure allows for the development of medications that can effectively target and alleviate pain and inflammation.
Used in Agrochemical Synthesis:
In the agrochemical industry, (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol is utilized as a key intermediate in the creation of compounds designed to protect crops and enhance agricultural productivity. Its properties contribute to the effectiveness and safety of these chemicals in the agricultural sector.
Used in Chemical Intermediates:
(R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol also serves as an important chemical intermediate in the synthesis of a wide range of products. Its versatility and unique properties make it a valuable component in the development of new materials and compounds across various chemical applications.

Upstream product

• 10297-73-1 4-(methanesulfonyl)acetophenone 

Downstream Products

• 726192-98-9 4-{(S)-4-[(S)-1-(4-Methanesulfonyl-phenyl)-ethyl]-3-methyl-piperazin-1-yl}-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 726192-95-6 (S)-4-[(S)-1-(4-Methanesulfonyl-phenyl)-ethyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 726192-09-2 Methanesulfonic acid (R)-1-(4-methanesulfonyl-phenyl)-ethyl ester 

Relevant articles and documents

RETRACTED ARTICLE: The Manganese(I)-Catalyzed Asymmetric Transfer Hydrogenation of Ketones: Disclosing the Macrocylic Privilege

The bis(carbonyl) manganese(I) complex [Mn(CO)2(1)]Br (2) with a chiral (NH)2P2 macrocyclic ligand (1) catalyzes the asymmetric transfer hydrogenation of polar double bonds with 2-propanol as the hydrogen source. Ketones (43 substrates) are reduced to alcohols in high yields (up to >99 %) and with excellent enantioselectivities (90–99 % ee). A stereochemical model based on attractive CH–π interactions is proposed.

Alternative Hydrogen Source for Asymmetric Transfer Hydrogenation in the Reduction of Ketones

cis-1,4-Butenediol is shown to be a highly active hydrogen source for asymmetric transfer hydrogenation in the reduction of ketones. With the use of a ruthenium catalyst, cis-1,4-butenediol is isomerised and subsequently oxidised to a lactone as an irreversible step, which provides the driving force for the asymmetric reduction of ketones.

NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS

The present invention relates to a compound of general Formula (XX), its formation and its use in asymmetric catalysis. In Formula (XX) R and R31 are independently —COOR3, —R4COOR3, —R4CHO, —R4COR3, —R4CONR5R6, —R4COX, —R4OP(═O)(OH)2, —R4P(═O)(OH)2), —R4C(O)C(R3)CR5R6 and —R4CO2COR3. In addition, R31 may also be hydrogen. R3, R5 and R6 are independently hydrogen, an aliphatic group with a main chain having 1 to about 20 carbon atoms, an alicyclic group, an aromatic group, an arylaliphatic group or an arylalicyclic group, comprising 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si. R4 an aliphatic bridge with a main chain having 1 to about 20 carbon atoms, an alicyclic bridge, an aromatic bridge, an arylaliphatic bridge or an arylalicyclic bridge, comprising 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si, and X is halogen. In Formula (XX) R30 is —C(OH)R1R2 or —COOR14, wherein R1, R2 and R14 are independently hydrogen, an aliphatic group with a main chain having 1 to about 20 carbon atoms, an alicyclic group, an aromatic group, an arylaliphatic group or an arylalicyclic group, comprising 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si.

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten

Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm